Andreas Rummel, PhD, is Senior Group Leader at the Institut für Toxikologie at the Medizinische Hochschule Hannover (MHH), Hannover, Germany. Dr Rummel obtained his PhD in biochemistry with the thesis, Characterization of the Cell-Binding Domain of Clostridial Neurotoxins. In 2003, he joined the Institut für Toxikologie at MHH as a postdoctoral fellow, and in 2004, he joined toxogen GmbH, an enterprise developing clostridial neurotoxins as therapeutics and diagnostic tools.
Dr. Rummel’s expertise in the field of clostridial neurotoxins is well documented in his authorship of 54 publications in peer-reviewed scientific journals. He has also published 13 review articles/book chapters on the basic mechanisms of clostridial neurotoxins and co-edited the book Botulinum Neurotoxins.
He serves as ad hoc reviewer for numerous top-tier scientific journals, including Nature, PLOS One, FEBS Journal, Toxicon, Nature Structural & Molecular Biology, Infection and Immunity, Cellular and Molecular Life Sciences, and Biochemistry. In 2016, he was appointed editor of the peer-reviewed journal Toxins. In addition, Dr. Rummel is the inventor on eight patent applications and five worldwide patent families.
Since 2015, Dr. Rummel has served as a board member of the International Neurotoxin Association (INA), which organizes the biennial TOXINS conferences. He is also a member of several scientific committees organizing conferences related to research on bacterial protein toxins and was Scientific Sub-Committee Co-Chair of the 2015 TOXINS Conference. He has received numerous invitations to present his scientific research in the United States, Europe, and Asia. He serves as a litigation expert at the United States Patent and Trademark Office.